• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

靶向血脑屏障开放促进脑胶质母细胞瘤的多柔比星/抗 PD-1 化学免疫治疗。

Targeted opening of the blood-brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma.

机构信息

Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France.

Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France.

出版信息

Oncoimmunology. 2024 Jul 27;13(1):2385124. doi: 10.1080/2162402X.2024.2385124. eCollection 2024.

DOI:10.1080/2162402X.2024.2385124
PMID:39076248
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11285269/
Abstract

Doxorubicin is a prototypical inducer of immunogenic cell death (ICD) that sensitizes to subsequent immunotherapy by PD-1 blockade. However, this systemic drug combination fails against glioblastoma, hidden behind the blood-brain barrier (BBB). A recent work delineates a biophysical method for BBB permeabilization that yields effective preclinical effects of chemoimmunotherapy.

摘要

多柔比星是一种典型的免疫原性细胞死亡（ICD）诱导剂，通过 PD-1 阻断可增强对后续免疫治疗的敏感性。然而，这种全身药物联合治疗在血脑屏障（BBB）的阻碍下，对胶质母细胞瘤无效。最近的一项工作描述了一种用于 BBB 通透性的生物物理方法，该方法可产生有效的化疗免疫治疗的临床前效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba6/11285269/db18415f50ce/KONI_A_2385124_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba6/11285269/db18415f50ce/KONI_A_2385124_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba6/11285269/db18415f50ce/KONI_A_2385124_F0001_OC.jpg

相似文献

1
Targeted opening of the blood-brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma.靶向血脑屏障开放促进脑胶质母细胞瘤的多柔比星/抗 PD-1 化学免疫治疗。
Oncoimmunology. 2024 Jul 27;13(1):2385124. doi: 10.1080/2162402X.2024.2385124. eCollection 2024.
2
Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas.超声介导的阿霉素向脑部的递送导致免疫调节，并改善了对脑胶质瘤中 PD-1 阻断的反应。
Nat Commun. 2024 Jun 6;15(1):4698. doi: 10.1038/s41467-024-48326-w.
3
Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma.针对血脑屏障的靶向调控提高缺氧修饰纳米颗粒和免疫检查点阻断抗体治疗脑胶质母细胞瘤的疗效。
ACS Appl Mater Interfaces. 2021 Mar 17;13(10):11657-11671. doi: 10.1021/acsami.1c00347. Epub 2021 Mar 8.
4
Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.针对多形性胶质母细胞瘤的 PD-1/PD-L1 通路：临床前证据和临床干预。
Int Immunopharmacol. 2021 Apr;93:107403. doi: 10.1016/j.intimp.2021.107403. Epub 2021 Feb 12.
5
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).用抗 CD40 和有丝分裂纺锤体检验点控制器 BAL101553（利斯伐他汀）治疗 ICB 耐药性神经胶质瘤。
JCI Insight. 2021 Sep 22;6(18):e142980. doi: 10.1172/jci.insight.142980.
6
Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival.透明质酸缀合物联合免疫原性细胞死亡诱导剂和 CpG 用于胶质母细胞瘤局部化疗免疫治疗可引发免疫反应并诱导长期生存。
Biomaterials. 2023 Mar;294:122006. doi: 10.1016/j.biomaterials.2023.122006. Epub 2023 Jan 21.
7
Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.胶质母细胞瘤中免疫检查点阻断的临床试验研究
Curr Treat Options Oncol. 2017 Aug;18(8):51. doi: 10.1007/s11864-017-0492-y.
8
Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.纳米胶束保护紫杉醇的免疫激活作用，并使肿瘤对抗 PD-1 免疫治疗敏感。
Theranostics. 2020 Jul 9;10(18):8382-8399. doi: 10.7150/thno.45391. eCollection 2020.
9
Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth.创新型肿瘤治疗设备OM-100通过增强抗PD-1免疫疗法对胶质母细胞瘤生长的抗肿瘤作用。
Sci Rep. 2024 Aug 8;14(1):18444. doi: 10.1038/s41598-024-67437-4.
10
Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.免疫检查点阻断疗法治疗胶质母细胞瘤的研究进展。
Front Immunol. 2020 Nov 30;11:592612. doi: 10.3389/fimmu.2020.592612. eCollection 2020.

引用本文的文献

1
Overcoming immunotherapy resistance in glioblastoma: challenges and emerging strategies.克服胶质母细胞瘤中的免疫治疗耐药性：挑战与新兴策略
Front Pharmacol. 2025 Mar 28;16:1584688. doi: 10.3389/fphar.2025.1584688. eCollection 2025.

本文引用的文献

1
Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas.超声介导的阿霉素向脑部的递送导致免疫调节，并改善了对脑胶质瘤中 PD-1 阻断的反应。
Nat Commun. 2024 Jun 6;15(1):4698. doi: 10.1038/s41467-024-48326-w.
2
Targeting immunogenic cell stress and death for cancer therapy.针对免疫原性细胞应激和死亡的癌症治疗。
Nat Rev Drug Discov. 2024 Jun;23(6):445-460. doi: 10.1038/s41573-024-00920-9. Epub 2024 Apr 15.
3
A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives.
免疫疗法治疗高级别胶质瘤的系统评价：从过去中学习，塑造未来的视角。
Neurol Sci. 2024 Jun;45(6):2561-2578. doi: 10.1007/s10072-024-07350-w. Epub 2024 Feb 3.
4
Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.胶质母细胞瘤免疫治疗：现有策略的系统评价及进展展望。
Int J Mol Sci. 2023 Oct 10;24(20):15037. doi: 10.3390/ijms242015037.
5
Immunosurveillance in clinical cancer management.临床癌症管理中的免疫监测。
CA Cancer J Clin. 2024 Mar-Apr;74(2):187-202. doi: 10.3322/caac.21818. Epub 2023 Oct 25.
6
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.替莫唑胺联合纳武利尤单抗或安慰剂治疗新诊断伴甲基化 MGMT 启动子的胶质母细胞瘤的 III 期临床试验。
Neuro Oncol. 2022 Nov 2;24(11):1935-1949. doi: 10.1093/neuonc/noac116.
7
Targeting immunoliposomes to EGFR-positive glioblastoma.针对表皮生长因子受体阳性脑胶质瘤的免疫脂质体。
ESMO Open. 2022 Feb;7(1):100365. doi: 10.1016/j.esmoop.2021.100365. Epub 2022 Jan 5.
8
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.纳武利尤单抗对比贝伐珠单抗治疗复发性胶质母细胞瘤患者的效果：CheckMate 143 期随机临床试验。
JAMA Oncol. 2020 Jul 1;6(7):1003-1010. doi: 10.1001/jamaoncol.2020.1024.
9
Innate immune memory in the brain shapes neurological disease hallmarks.大脑中的先天免疫记忆塑造神经疾病特征。
Nature. 2018 Apr;556(7701):332-338. doi: 10.1038/s41586-018-0023-4. Epub 2018 Apr 11.
10
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.阿霉素诱导的肿瘤细胞死亡的半胱天冬酶依赖性免疫原性。
J Exp Med. 2005 Dec 19;202(12):1691-701. doi: 10.1084/jem.20050915.